Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey. Show More...
-
Website https://www.protalix.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.42 USD
-
Last Updated 14-07-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -3.6 -4.3 -1.3 -3.0 -3.2 6.1 -2.9 -6.37 -1.8 -1.23 -1.23 Dividends USD Payout Ratio % * Shares Mil 8.0 8.0 9.0 9.0 9.0 9.0 10.0 13.0 15.0 15.0 15.0 Book Value Per Share * USD -1.4 -2.03 -0.36 -1.79 -5.1 -6.86 -1.22 -1.81 -4.38 -4.77 -2.17 Free Cash Flow Per Share * USD -5.72 -3.71 -0.16 -2.82 -3.23 -2.77 -2.95 -2.91 0.9 -1.38 Return on Assets % -35.49 -62.69 -17.8 -28.94 -31.22 66.06 -32.72 -110.42 -39.68 -34.31 -34.31 Financial Leverage (Average) 8.94 Return on Equity % Return on Invested Capital % -18.87 Interest Coverage -5.07 -6.3 -1.74 -7.77 -2.44 -1.29 -1.29 Current Ratio 2.45 1.74 2.38 3.67 2.5 7.64 1.09 2.75 2.09 0.81 0.81 Quick Ratio 2.39 1.72 2.08 3.31 2.16 6.8 0.97 2.32 1.68 0.56 0.56 Debt/Equity 6.63